ECUR 506
Alternative Names: ECUR-506; GTP-506; iECURE-OTCLatest Information Update: 16 Jan 2025
At a glance
- Originator iECURE
- Class Gene therapies
- Mechanism of Action Gene transference; Ornithine carbamoyltransferase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 09 Jan 2025 Efficacy and adverse events data from the phase I/II OTC-HOPE trial in Ornithine carbamoyltransferase deficiency disease released by iECURE
- 08 May 2024 ECUR 506 receives Fast Track designation for Ornithine carbamoyltransferase deficiency disease [IV,Infusion] in USA
- 30 Apr 2024 Phase-I/II clinical trials in Ornithine carbamoyltransferase deficiency disease (In infants, In neonates) in Australia, Spain (IV) (NCT06255782)